These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35370750)

  • 1. Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis.
    Zhou Y; Li J; Wang L; Zhu X; Zhang M; Zheng J
    Front Pharmacol; 2022; 13():833679. PubMed ID: 35370750
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute Kidney Injury Associated With Remdesivir: A Comprehensive Pharmacovigilance Analysis of COVID-19 Reports in FAERS.
    Wu B; Luo M; Wu F; He Z; Li Y; Xu T
    Front Pharmacol; 2022; 13():692828. PubMed ID: 35401177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remdesivir for COVID-19 and acute kidney injury: disproportionality analysis of data from the U.S. Food and Drug Administration Adverse Event Reporting System.
    Li X; Zhou L; Gaggl M; Kinlaw AC; Gou Z; Xu Y; Wei J; Wang T
    Int J Clin Pharm; 2023 Apr; 45(2):509-514. PubMed ID: 36964312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
    Orogun L; Chyou TY; Nishtala PS
    Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database.
    Silva NAO; Zara ALSA; Figueras A; Melo DO
    Cad Saude Publica; 2021; 37(10):e00077721. PubMed ID: 34787281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
    Touafchia A; Bagheri H; Carrié D; Durrieu G; Sommet A; Chouchana L; Montastruc F
    Clin Microbiol Infect; 2021 Feb; 27(5):791.e5-8. PubMed ID: 33647441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced liver injury associated with lopinavir-ritonavir in patients with COVID-19: a disproportionality analysis of U.S. food and drug administration adverse event reporting system (FAERS) data.
    Tang H; Zhou L; Li X; Kinlaw AC; Yang JY; Moon AM; Barnes EL; Wang T
    Int J Clin Pharm; 2021 Aug; 43(4):1116-1122. PubMed ID: 34328585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.
    Garcia P; Revet A; Yrondi A; Rousseau V; Degboe Y; Montastruc F
    Drug Saf; 2020 Dec; 43(12):1315-1322. PubMed ID: 33078372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
    Gérard AO; Laurain A; Fresse A; Parassol N; Muzzone M; Rocher F; Esnault VLM; Drici MD
    Clin Pharmacol Ther; 2021 Apr; 109(4):1021-1024. PubMed ID: 33340409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
    Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
    Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure.
    Kamo M; Sogawa R; Shimanoe C
    In Vivo; 2024; 38(4):1841-1846. PubMed ID: 38936945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
    Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
    J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System.
    Alsuhaibani DS; Edrees HH; Alshammari TM
    Saudi Pharm J; 2023 Jul; 31(7):1360-1366. PubMed ID: 37304358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Agranulocytosis and secondary infection related to JAK inhibitors and IL-6 receptor blockers: a disproportionality analysis using the US Food and drug administration adverse event reporting system.
    Wei C; Yin W; Hu T; Zhang J; Dan H; Wu B
    Front Pharmacol; 2023; 14():1323240. PubMed ID: 38264533
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study.
    Liu H
    Front Pharmacol; 2024; 15():1353848. PubMed ID: 39148544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
    Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
    Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system.
    Zhang J; Guo Y; Wei C; Yan Y; Shan H; Wu B; Wu F
    Front Pharmacol; 2024; 15():1363501. PubMed ID: 38974040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.